A Plus Research Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$38,742	7
2020	Research	$7,850	13
2019	Research	$9,200	2

Breakdown

Who paid Research payments · program years 2019–2021

Gilead Sciences, Inc. $41,314 8 payments
Cosette Pharmaceuticals Inc. $9,700 3 payments
Esperion Therapeutics, Inc. $4,778 11 payments

Studies the money was for Research payments · program years 2019–2021

Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $12,494 1 payment
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $10,528 1 payment
Development of A New Hemorrhoid Patient Reported Out Come Measure. $9,700 3 payments
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $9,599 1 payment
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $4,778 11 payments
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $2,572 1 payment
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $2,109 1 payment
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $1,486 1 payment
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $1,408 1 payment
Phase 2, Blinded, Randomized, Placebo-Controlled Studies Evaluating the Safety and Efficacy of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis $1,118 1 payment

What the money was spent on Research payments · program years 2019–2021

Other $9,700 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.